Clinical Trials
22 trialsNCT04013685 2026-06-02
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Orca Biosystems, Inc.
Phase 1 Active not recruiting
NCT02942290 2026-05-18
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
AbbVie
Phase 1 Active not recruiting
NCT05583552 2026-05-12
IMpress
GCP-Service International West GmbH
Phase 2 Active not recruiting
NCT05428969 2026-04-23
BEXMAB
Faron Pharmaceuticals Ltd
Phase 1/2 Active not recruiting
NCT02381886 2026-04-13
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
Novartis
Phase 1 Active not recruiting
NCT04279847 2026-04-01
LIMBER
Incyte Corporation
Phase 1 Active not recruiting
NCT05552469 2026-03-27
Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases
Novartis
Phase 1 Active not recruiting
NCT04635384 2026-03-18
ACROBAT
CareDx
Active not recruiting
NCT05316701 2026-03-04
Orca-T
Orca Biosystems, Inc.
Phase 3 Active not recruiting
NCT06846606 2026-03-03
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
Auron Therapeutics, Inc.
Phase 1 Active not recruiting
NCT05201066 2026-01-07
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
Novartis
Phase 2 Active not recruiting
NCT02598661 2026-01-05
Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Geron Corporation
Phase 2/3 Active not recruiting
NCT04891757 2025-07-10
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies
Foghorn Therapeutics Inc.
Phase 1 Active not recruiting
NCT04603001 2025-06-27
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
Eli Lilly and Company
Phase 1 Active not recruiting
NCT04730258 2025-05-18
TWT-202
Treadwell Therapeutics, Inc
Phase 1/2 Active not recruiting
NCT05883956 2025-03-20
PREFER-HMA
Otsuka Australia Pharmaceutical Pty Ltd
Phase 3 Active not recruiting
NCT04623944 2024-12-27
NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS
Nkarta, Inc.
Phase 1 Active not recruiting
NCT03927261 2024-11-08
PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS
Precigen, Inc
Phase 1 Active not recruiting
NCT01744223 2022-07-12
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
Bellicum Pharmaceuticals
Phase 1/2 Active not recruiting
NCT02477878 2022-07-12
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
Bellicum Pharmaceuticals
Phase 1 Active not recruiting
NCT03301168 2022-07-12
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
Bellicum Pharmaceuticals
Phase 1/2 Active not recruiting
NCT03459170 2022-07-12
Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant
Bellicum Pharmaceuticals
Phase 1 Active not recruiting